Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF)

Leading North American Specialty Pharmaceutical Company focused on hematology, rheumatology, auto-immune disease, specialty oncology and pediatrics.

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors https://t.co/Fps9Bp6WwH

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date https://t.co/nlTQx2LISs

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation https://t.co/YH47BreOE5

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection https://t.co/kIgHvZL0AS

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Schedules Third Fiscal Quarter 2026 Conference Call https://t.co/HkxeyukL1x

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

For more than a decade IXINITY® has been a treatment option for those living with hemophilia B. FDA-approved in April 2015, we celebrate the 10th "Approve-iversary" of #IXINITY by looking back into the archives. Please see Full Prescribing Information at https://t.co/sHsV9mHo5j

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Read the full press release: https://t.co/qPLNjkWA0Z

#MedexusInc $MDP.CA $MEDXF

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares

Read the full press release: https://t.co/2NwHNz8A4z

#MedexusInc $MDP.CA $MEDXF

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Read the full press release: https://t.co/bXmtD7clRV

#MedexusInc $MDP.CA $MEDXF

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Schedules Second Fiscal Quarter 2026 Conference Call

Read the full press release:https://t.co/F8WhXM7u3b

#MedexusInc $MDP.CA $MEDXF

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors https://t.co/y1gwGxf5k1

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection https://t.co/4gdV0hlys3

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Schedules First Fiscal Quarter 2026 Conference Call https://t.co/CYphcxniJL

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 https://t.co/GJXBfJTN6E

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States https://t.co/RASzx33QqT

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call https://t.co/hX5nW7vJ3e

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Review our April 17 news release for more information: https://t.co/OknmulMi3y

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

"This development is another important reimbursement milestone for Trecondyv® because we have now achieved public reimbursement of Trecondyv® in Canada's three most populous provinces, representing around three quarters of Canadians," said Richard Labelle, Medexus COO

[Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) @MedexusInc]

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada https://t.co/amTh2FQDU5